absolutely spot article steinman bero chren landefeld course lisa bero train publishing gold mine fascinating research tobacco drug industries years i come expect practicing mental health professional colleagues aware neurontin gabapentin never approved use psychiatric populations course stop reps aggressively marketing drug psych populations i including part story much article steinman bero la chren landefeld cs narrative review promotion gabapentin analysis internal industry documents annals internal medicine interesting quote article regarding intersection marketing research case neurontin however cases parke davis employed publication strategy goal use research means gain fda approval new indications disseminate information widely possible world medical literature generating excitement market stimulating label prescribing despite lack fda approval strategy focused primarily expanding gabapentin use neuropathic pain bipolar disorders detailed decision analyses projected greatest revenue potential success strategy depended part publications favorable gabapentin employees parke davis felt obligation publish studies unfavorable results number instances results published however management expressed concern negative results could harm promotional efforts several documents indicate intention publish publicize results reflected favorably gabapentin stated marketing assessment results recommended exploratory trials neuropathic pain positive publicized medical congresses published italics added similarly discussing nearly identical trials yielded conflicting results gabapentin seizure monotherapy core marketing team concluded results negative trial published positive trial published could locate negative trial pubmed search p